Carl Zeiss Meditec
A global medical technology company providing diagnostic, therapeutic, and surgical solutions, particularly for ophthalmology and microsurgery.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Carl Zeiss Meditec AG is a Germany-based medical technology company operating within the Carl Zeiss Group and doing business under the ZEISS Medical Technology name. Established in 2002 and headquartered in Jena, the company develops and supplies equipment, systems, and consumables for clinical diagnosis and treatment. Its principal activities are concentrated in ophthalmology and microsurgery, with additional applications in areas including dentistry, oncology, neurosurgery, and other medical specialties. The company’s ophthalmology portfolio spans diagnostic imaging, refractive and cataract surgery, retinal treatment, and related clinical workflows. Its products include optical and digital imaging platforms, laser systems, surgical visualization equipment, and intraocular lenses. The CIRRUS family represents its optical coherence tomography and ophthalmic imaging activities, while its refractive-surgery portfolio includes the ReLEx SMILE laser procedure platform. In surgical settings, ZEISS systems are used to magnify, visualize, and document procedures, particularly in ophthalmic and microsurgical work. Carl Zeiss Meditec combines engineering and optical expertise associated with the wider Carl Zeiss Group with medical-device development and regulatory processes. Its products are sold internationally through a global commercial and service organization, supporting hospitals, clinics, physicians, and other healthcare providers. The business model includes capital equipment, software and workflow solutions, procedure-related products, and recurring consumables such as intraocular lenses. The company has expanded both organically and through acquisitions. In 2018, it received United States Food and Drug Administration premarket approval for its ReLEx SMILE laser system and announced the acquisition of IanTech, a Reno, Nevada-based developer associated with cataract-surgery technology. In 2019, it introduced the CIRRUS 6000 at the European Society of Retina Specialists congress, extending its ophthalmic imaging offering. These developments illustrate the company’s emphasis on minimally invasive procedures, advanced visualization, diagnostic precision, and integrated clinical workflows. Carl Zeiss Meditec is publicly listed under the ticker AFX and remains part of the privately controlled Carl Zeiss Group. Its market identity is built around premium medical optics, imaging, precision surgery, and the integration of hardware, software, and procedure technologies. The brand is internationally active and is commonly presented to customers as ZEISS Medical Technology.
History
Carl Zeiss Meditec was established in 2002 as a medical technology company associated with the Carl Zeiss Group. From its base in Jena, Germany, it developed a business focused primarily on ophthalmology and microsurgery, applying the group’s longstanding capabilities in optics, precision engineering, and visualization to clinical equipment and procedure technologies. Its activities expanded beyond individual optical instruments into broader medical workflows. The company’s portfolio came to include diagnostic imaging, optical coherence tomography, refractive surgery, cataract and retinal treatment, surgical microscopes, visualization platforms, intraocular lenses, and related software. Although ophthalmology remained its principal field, the company also identified applications in dentistry, oncology, neurosurgery, and other medical areas. A significant part of the company’s development has involved minimally invasive and image-guided treatment. Its ReLEx SMILE system addressed refractive surgery, while its CIRRUS product family supported ophthalmic imaging and clinical assessment. Surgical microscopes and visualization systems extended the brand’s role from diagnosis into the operating room, particularly in microsurgical procedures. In October 2018, Carl Zeiss Meditec received FDA premarket approval for its ReLEx SMILE laser system in the United States. The same month, it announced the acquisition of IanTech, a Reno, Nevada-based medical-device company, for an undisclosed amount. The transaction broadened the company’s cataract-surgery-related capabilities and reflected its use of acquisitions to complement internal product development. In September 2019, Carl Zeiss Meditec launched the CIRRUS 6000 at the European Society of Retina Specialists congress. The product launch reinforced the importance of retinal imaging and high-throughput diagnostic workflows within its ophthalmology business. Carl Zeiss Meditec operates internationally and is part of the larger Carl Zeiss Group. It is publicly listed under the ticker AFX, while the wider group remains the company’s parent organization. The medical business is marketed globally as ZEISS Medical Technology and continues to combine diagnostic systems, therapeutic devices, surgical visualization, consumables, and software-oriented clinical solutions.
- 2019
CIRRUS 6000 launched
[1]The CIRRUS 6000 was launched at the European Society of Retina Specialists congress.
- 2018
FDA approval for ReLEx SMILE
[1]The ReLEx SMILE laser system received United States FDA premarket approval.
- 2018
IanTech acquisition announced
[1]Carl Zeiss Meditec announced the acquisition of IanTech, a Reno, Nevada-based medical-device company, for an undisclosed amount.
- 2002
Company founded
[1]Carl Zeiss Meditec was established as a medical technology company within the Carl Zeiss Group, with an emphasis on ophthalmology and microsurgery.
Products and positioning
A premium medical technology provider centered on precision optics, advanced imaging, surgical visualization, and procedure-focused solutions for ophthalmology and microsurgery.
Ophthalmic imaging and optical coherence tomography
CIRRUS
The CIRRUS family comprises ophthalmic imaging systems used in clinical examination and retinal assessment. The platform is associated with optical coherence tomography and related diagnostic workflows, helping eye-care professionals visualize ocular structures and support diagnosis and treatment planning.
Ophthalmic imaging system · 2019
CIRRUS 6000
The CIRRUS 6000 is an ophthalmic imaging product introduced in 2019. It was presented as part of the company’s retinal and diagnostic imaging portfolio at the European Society of Retina Specialists congress.
Refractive surgery laser system · 2018
ReLEx SMILE
ReLEx SMILE is a laser platform for refractive eye surgery. Carl Zeiss Meditec received United States FDA premarket approval for the system in 2018, marking a significant regulatory milestone for the company’s refractive-surgery business.
Surgical visualization
ZEISS ophthalmic surgical microscopes
Carl Zeiss Meditec supplies surgical microscopes and visualization systems for ophthalmic and microsurgical procedures. These products apply precision optics and magnification to operating-room work, supporting visualization during delicate interventions.
Ophthalmic implant
Intraocular lenses
Intraocular lenses form part of the company’s ophthalmic consumables and procedure-related portfolio. They are used in eye surgery, including cataract-related procedures, and complement Carl Zeiss Meditec’s diagnostic and surgical equipment businesses.
Brand decisions
2019
Launch of CIRRUS 6000Product launchBackground
The company continued to develop its ophthalmic imaging portfolio for retinal and clinical diagnostic applications.
Action taken
Carl Zeiss Meditec launched the CIRRUS 6000 at the European Society of Retina Specialists congress.
Aftermath
The launch strengthened the CIRRUS line within the company’s ophthalmic imaging offering.
2018
Regulatory introduction of ReLEx SMILE in the United StatesProduct launchBackground
Carl Zeiss Meditec was seeking regulatory clearance for its refractive-surgery laser system in the United States.
Action taken
The company obtained FDA premarket approval for ReLEx SMILE.
Aftermath
The approval enabled the system to be marketed for its approved use in the United States.
2018
Acquisition of IanTech announcedM&ABackground
Carl Zeiss Meditec announced a transaction involving IanTech, a Reno, Nevada-based medical-device company.
Action taken
The company announced the acquisition of IanTech; the transaction value was not disclosed in the reference material.
Aftermath
The acquisition expanded Carl Zeiss Meditec’s presence in cataract-surgery-related medical technology.
Recent events
- 2019
CIRRUS 6000 introduced at European retina congress[1]
Product launch · Product generation
The company launched the CIRRUS 6000 at the 2019 congress of the European Society of Retina Specialists.
- 2018
Carl Zeiss Meditec receives FDA premarket approval for ReLEx SMILE[1]
Regulation · Product launch
The company obtained United States FDA premarket approval for its ReLEx SMILE laser system, a refractive-surgery platform.
- 2018
Carl Zeiss Meditec announces acquisition of IanTech[1]
M&A
Carl Zeiss Meditec announced the acquisition of IanTech, a medical-device company based in Reno, Nevada. The transaction value was not disclosed in the reference material.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/carl-zeiss-meditec · Editorial policy · How profiles are compiled